SUNNYVALE, CA, USA I February 27, 2015 I Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that longer-term toxicology studies for its newly developed Bruton’s tyrosine kinase (BTK) inhibitor for rheumatoid arthritis, or RA, have been completed. The results of these preclinical evaluations have been communicated to the U.S. Food and Drug Administration. The feedback received from the Agency is supportive of the completion of the ongoing first-in-human study. Additional preclinical work is required to begin a Phase II clinical development program in autoimmune diseases with this investigational compound. The Company does not anticipate initiating a Phase II study until additional preclinical work is successfully completed. Further updates on the progress of these efforts will be provided when appropriate.
About Pharmacyclics
Pharmacyclics, Inc. (NASDAQ: PCYC) is a biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. The company’s mission is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medical needs. It will do so by identifying and controlling promising product candidates based on scientific development and administrative expertise, developing its products in a rapid, cost-efficient manner and, pursuing commercialization and/or development partners when and where appropriate.
Pharmacyclics markets IMBRUVICA and has three product candidates in clinical development and several preclinical molecules in lead optimization. The company is committed to high standards of ethics, scientific rigor and operational efficiency as it moves each of these programs to commercialization. Pharmacyclics is headquartered in Sunnyvale, CA. To learn more, please visit www.pharmacyclics.com.
SOURCE: Pharmacyclics
Post Views: 26
SUNNYVALE, CA, USA I February 27, 2015 I Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that longer-term toxicology studies for its newly developed Bruton’s tyrosine kinase (BTK) inhibitor for rheumatoid arthritis, or RA, have been completed. The results of these preclinical evaluations have been communicated to the U.S. Food and Drug Administration. The feedback received from the Agency is supportive of the completion of the ongoing first-in-human study. Additional preclinical work is required to begin a Phase II clinical development program in autoimmune diseases with this investigational compound. The Company does not anticipate initiating a Phase II study until additional preclinical work is successfully completed. Further updates on the progress of these efforts will be provided when appropriate.
About Pharmacyclics
Pharmacyclics, Inc. (NASDAQ: PCYC) is a biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. The company’s mission is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medical needs. It will do so by identifying and controlling promising product candidates based on scientific development and administrative expertise, developing its products in a rapid, cost-efficient manner and, pursuing commercialization and/or development partners when and where appropriate.
Pharmacyclics markets IMBRUVICA and has three product candidates in clinical development and several preclinical molecules in lead optimization. The company is committed to high standards of ethics, scientific rigor and operational efficiency as it moves each of these programs to commercialization. Pharmacyclics is headquartered in Sunnyvale, CA. To learn more, please visit www.pharmacyclics.com.
SOURCE: Pharmacyclics
Post Views: 26
